大行評級丨大華繼顯:市場不明朗因素所帶動的港股高成交速度不太可能持續,降港交所目標價至394港元
大華繼顯發表研究報告指,在中國人工智能熱潮帶動日均成交總額強勁表現下,預期港交所(0388.HK)今年第一季純利將按年增長36.3%。雖然美國關稅衝擊後成交量急升,但相信市場不明朗因素所帶動的高成交速度不太可能持續,預期隨著去風險情緒瀰漫,日均交易總額將逐步放緩。在近期股價回落後,該行稱港交所估值並不特別昂貴,在考慮本年至今市場數據及提升日均成交總額預測後,上調港交所2025年的盈測4.2%,惟下調其2026及27年盈測分別3.7%及1%,維持其“買入”評級,目標價由418港元下調至394港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.